Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and pirfenidone May Offset Negative Effect of Patent Expiries

NEW YORK, Sept. 6, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and pirfenidone May Offset Negative Effect of Patent Expiries

http://www.reportlinker.com/p0610893/Respiratory-Disorders-Therapeutics-Market-to-2017---Novel-Pipeline-Molecules-such-as-VX-770-and-pirfenidone-May-Offset-Negative-Effect-of-Patent-Expiries.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and pirfenidone May Offset Negative Effect of Patent Expiries

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and pirfenidone May Offset Negative Effect of Patent Expiries", which provides insights into the global respiratory disorders market and market forecast until 2017. The report provides an in-depth analysis of the top seven respiratory disorders indications, which includes asthma, COPD, pulmonary arterial hypertension, idiopathic pulmonary fibrosis, allergic rhinitis, cystic fibrosis and bronchitis. In addition, the report also includes insights into the respiratory disorders R&D pipeline. GBI research analysis estimated that 55% of the revenues are generated by AstraZeneca, GSK, Novartis, Merck, Roche, UCB Inc, Actelion and Takeda. Other companies generate 45% of the revenues in the respiratory disorders therapeutics market. AstraZeneca is the leading company in the respiratory disorders therapeutics market. The large amount of fragmentation in the market provides significant scope for consolidation through mergers and acquisitions. Strategic through acquisition accounted for 53% of the M&A deals.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research analysis shows that the overall respiratory disorders market for the seven indications asthma, COPD, Pulmonary arterial hypertension, idiopathic pulmonary fibrosis, allergic rhinitis, cystic fibrosis and bronchitis was valued at $29.4 billion in 2010. The market is expected to witness a growth at a CAGR of 3% for the forecast period and will reach $36.2 billion by 2017. The moderate rate of growth is attributable to patent expiry of branded products. The top pharmaceutical companies in the respiratory disorders market are companies such as AstraZeneca, GlaxoSmithKline, Merck, Actelion, and Novartis.

Scope

- The report analyzes market characterization, pipeline analysis and key M&A trends in the asthma, COPD, pulmonary arterial hypertension, idiopathic pulmonary fibrosis, allergic rhinitis, cystic fibrosis and bronchitis therapeutics market.

- Data and analysis on the global respiratory disorders market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.

- Annualized market data for the respiratory disorders market from 2002-2010 with forecasts to 2017.

- Market data on the therapeutic landscape which covers asthma, COPD, pulmonary arterial hypertension, idiopathic pulmonary fibrosis, allergic rhinitis, cystic fibrosis and bronchitis, including market size, market share and annual cost of therapy, treatment flow algorithm and branded and generic share.

- Key drivers and restraints that have had a significant impact on the market and on each indication.

- The competitive landscape of the global respiratory disorders therapeutics market which includes companies such as AstraZeneca, GlaxoSmithKline, Merck, Actelion, and Novartis.

- Key M&A activities and licensing agreements that took place from 2005-2011 in the global respiratory disorders market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Align your product portfolio to the markets with high growth potential.

- Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.

- Device a more tailored country strategy through the understanding of key drivers and barriers of the respiratory disorders market.

- Develop key strategic initiatives by understanding the key focus areas and top selling antibacterial molecules of leading companies.

- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 6

1.2 List of Figures 10

2 Respiratory Disorders Therapeutics Market to 2017 - Introduction 13

2.1 GBI Research Report Guidance 14

3 Respiratory Disorders Therapeutics Market to 2017 - Market Overview 15

3.1 Introduction 15

3.2 Revenue Forecasts for Respiratory Disorders Therapeutics Market 15

3.2.1 Revenues 15

3.2.2 Annual Cost of Therapy 20

3.3 Treatment Usage Patterns 21

3.4 Drivers and Barriers for Respiratory Disorders Therapeutics Market 23

3.4.1 Drivers for Respiratory Disorders 23

3.4.2 Barriers for Respiratory Disorders 24

4 Respiratory Disorders Therapeutics Market to 2017 - Geographical Landscape 25

4.1 The US 25

4.1.1 Revenue 25

4.1.2 Annual Cost of Therapy 26

4.1.3 Treatment Usage Pattern 27

4.2 Top Five Countries of Europe 29

4.2.1 Revenue 29

4.2.2 Annual Cost of Therapy 32

4.2.3 Treatment Usage Pattern 33

4.3 Japan 35

4.3.1 Revenue 35

4.3.2 Annual Cost of Therapy 36

4.3.3 Treatment Usage Pattern 37

5 Respiratory Disorders Therapeutics Market to 2017 - Therapeutic Landscape 39

5.1 Asthma 39

5.1.1 Introduction 39

5.1.2 Revenue 39

5.1.3 Annual Cost of Therapy 44

5.1.4 Treatment Usage Patterns 45

5.1.5 Treatment Flow Algorithm 47

5.1.6 Drivers and Barriers for Asthma 48

5.2 COPD 50

5.2.1 Introduction 50

5.2.2 Revenue 50

5.2.3 Annual Cost of Therapy 55

5.2.4 Treatment Usage Patterns 56

5.2.5 Treatment Flow Algorithm 58

5.2.6 Drivers and Barriers for COPD 59

5.3 Pulmonary Arterial Hypertension 60

5.3.1 Introduction 60

5.3.2 Revenue 62

5.3.3 Annual Cost of Therapy 66

5.3.4 Treatment Usage Patterns 67

5.3.5 Treatment Flow Algorithm 69

5.3.6 Drivers and Barriers for Pulmonary Arterial Hypertension 70

5.4 Cystic Fibrosis 71

5.4.1 Introduction 71

5.4.2 Revenue 71

5.4.3 Annual Cost of Therapy 76

5.4.4 Treatment Usage Patterns 77

5.4.5 Treatment Flow Algorithm 79

5.4.6 Drivers and Barriers for Cystic Fibrosis 80

5.5 Allergic Rhinitis 81

5.5.1 Introduction 81

5.5.2 Revenue 81

5.5.3 Annual Cost of Therapy 86

5.5.4 Treatment Usage Patterns 87

5.5.5 Treatment Flow Algorithm 88

5.5.6 Drivers and Barriers for Allergic Rhinitis 89

5.6 Idiopathic Pulmonary Fibrosis 90

5.6.1 Introduction 90

5.6.2 Revenue 90

5.6.3 Annual Cost of Therapy 94

5.6.4 Treatment Usage Patterns 95

5.6.5 Treatment Flow Algorithm 97

5.6.6 Drivers and Barriers for Idiopathic Pulmonary Fibrosis 98

5.7 Bronchitis 99

5.7.1 Introduction 99

5.7.2 Revenue 99

5.7.3 Annual Cost of Therapy 104

5.7.4 Treatment Usage Patterns 105

5.7.5 Treatment Flow Algorithm 107

5.7.6 Drivers and Barriers for Bronchitis 108

6 Respiratory Disorders Therapeutics Market to 2017 - Product Pipeline Analysis 109

6.1 Introduction 109

6.1.1 Research and Development Pipeline - Asthma 111

6.1.2 Research and Development Pipeline - COPD 117

6.1.3 Research and Development Pipeline - Pulmonary Arterial Hypertension 121

6.1.4 Research and Development Pipeline - Cystic Fibrosis 123

6.1.5 Research and Development Pipeline - Allergic Rhinitis 125

6.1.6 Research and Development Pipeline - Idiopathic Pulmonary Fibrosis 128

6.1.7 Research and Development Pipeline - Bronchitis 130

6.2 Profiles of Promising Drugs in the Respiratory Disorders Therapeutics Market 131

6.2.1 Bilastine 131

6.2.2 Sublivac (Extracts of Allergens) 131

6.2.3 Duonase (Azelastine + Fluticasone) 132

6.2.4 Riociguat 133

6.2.5 VX-770 133

6.2.6 Indacaterol 134

6.2.7 NVA237 (Glycopyrronium Bromide) 135

6.2.8 Aclidinium Bromide 136

7 Respiratory Disorders Therapeutics Market to 2017 - Competitive Landscape 137

7.1 Market Share Analysis: Respiratory Disorders Market 137

7.2 Drug Profile of Major Marketed Products 138

7.2.1 Advair Diskus (fluticasone propionate and salmeterol inhalation powder) 138

7.2.2 Symbicort (budesonide/formoterol fumarate dihydrate inhalation aerosol) 140

7.2.3 Singulair (montekeulast sodium) 141

7.2.4 Tracleer 142

7.2.5 Nasonex (mometasone furoate monohydrate) 143

7.3 Competitive Profiling 145

7.3.1 AstraZeneca 145

7.3.2 GlaxoSmithKline 147

7.3.3 Merck & Co., Inc. 149

7.3.4 Actelion 151

7.3.5 Novartis 153

8 Respiratory Disorders Therapeutics Market to 2017 - M&A Landscape 155

8.1 M&A Landscape 155

8.1.1 M&A Deals by Year 155

8.1.2 M&A Deals by Value 156

8.1.3 M&A Deals by Value ($) 156

8.1.4 M&A Deals by Geography 157

8.1.5 M&A Deals by Deal Type 158

8.1.6 M&A Deals by Deal Sub-Type 159

8.2 R&D Licensing Agreements 160

8.2.1 Deals by Year 160

8.2.2 Deals by Geography 161

8.2.3 Deals by Value ($) 162

8.2.4 Licensing Agreements by Value ($) 162

8.3 Co-Development Agreements 163

8.3.1 Deals by Year 163

8.3.2 Deals by Geography 164

9 Respiratory Disorders Therapeutics Market to 2017 - Appendix 165

9.1 Market Definitions 165

9.2 Abbreviations 165

9.3 Research Methodology 166

9.3.1 Coverage 166

9.3.2 Secondary Research 166

9.3.3 Primary Research 167

9.3.4 Section Wise Methodology 167

9.3.5 Expert Panel Validation 170

9.4 Contact Us 170

9.5 Disclaimer 171

9.6 Sources 171

1.1 List of Tables

Table 1: Respiratory Disorders Therapeutics Market, Global, Revenue ($bn), 2002-2010 15

Table 2: Respiratory Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 16

Table 3: Respiratory Disorders Therapeutics Market, Global, Geographical Segmentation ($bn), 2002-2010 17

Table 4: Respiratory Disorders Therapeutics Market, Global, Geographical Segmentation ($bn), 2010-2017 18

Table 5: Respiratory Disorders Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010 20

Table 6: Respiratory Disorders Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017 20

Table 7: Respiratory Disorders Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2010 21

Table 8: Respiratory Disorders Therapeutics Market, Global, Treatment Usage Patterns (million), 2010-2017 22

Table 9: Respiratory Disorders Therapeutics Market, The US, Revenue, ($bn), 2002-2010 25

Table 10: Respiratory Disorders Therapeutics Market, The US, Revenue Forecasts, ($bn), 2010-2017 25

Table 11: Respiratory Disorders Therapeutics Market, The US, Annual Cost of Therapy, ($), 2002-2010 26

Table 12: Respiratory Disorders Therapeutics Market, The US, Annual Cost of Therapy, ($), 2010-2017 26

Table 13: Respiratory Disorders Therapeutics Market, The US, Treatment Usage Patterns, (million), 2002-2010 27

Table 14: Respiratory Disorders Therapeutics Market, The US, Treatment Usage Patterns, (million), 2010-2017 28

Table 15: Respiratory Disorders Therapeutics Market, Top Five Countries, Revenue, ($bn), 2002-2010 29

Table 16: Respiratory Disorders Therapeutics Market, Top Five Countries, Revenue, ($bn), 2010-2017 29

Table 17: Respiratory Disorders Therapeutics Market, Top Five Countries of Europe, Revenue Share by Country, ($bn), 2002-2010 30

Table 18: Respiratory Disorders Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts, ($bn), 2010-2017 31

Table 19: Respiratory Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy, ($), 2002-2010 32

Table 20: Respiratory Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy, ($), 2010-2017 32

Table 21: Respiratory Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns, (million), 2002-2010 33

Table 22: Respiratory Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns, (million), 2010-2017 34

Table 23: Respiratory Disorders Therapeutics Market, Japan, Revenue, ($bn), 2002-2010 35

Table 24: Respiratory Disorders Therapeutics Market, Japan, Revenue Forecasts, ($bn), 2010-2017 35

Table 25: Respiratory Disorders Therapeutics Market, Japan, Annual Cost of Therapy, ($), 2002-2010 36

Table 26: Respiratory Disorders Therapeutics Market, Japan, Annual Cost of Therapy, ($), 2010-2017 36

Table 27: Respiratory Disorders Therapeutics Market, Japan, Treatment Usage Patterns, (million), 2002-2010 37

Table 28: Respiratory Disorders Therapeutics Market, Japan, Treatment Usage Patterns, (million), 2010-2017 38

Table 29: Asthma Therapeutics Market, Global, Revenue, ($bn), 2002-2010 40

Table 30: Asthma Therapeutics Market, Global, Revenue Forecasts, ($bn), 2010-2017 40

Table 31: Asthma Therapeutics Market, Global, Geographical Segmentation, ($bn), 2002-2010 41

Table 32: Asthma Therapeutics Market, Global, Geographical Segmentation, ($bn), 2010-2017 42

Table 33: Asthma Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2010 44

Table 34: Asthma Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010-2017 44

Table 35: Asthma Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002-2010 45

Table 36: Asthma Therapeutics Market, Global, Treatment Usage Patterns, (million), 2010-2017 46

Table 37: COPD Therapeutics Market, Global, Revenue, ($m), 2002-2010 51

Table 38: COPD Therapeutics Market, Global, Revenue Forecasts, ($m), 2010-2017 51

Table 39: COPD Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2010 52

Table 40: COPD Therapeutics Market, Global, Geographical Segmentation, ($m), 2010-2017 53

Table 41: COPD Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2010 55

Table 42: COPD Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010-2017 55

Table 43: COPD Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002-2010 56

Table 44: COPD Therapeutics Market, Global, Treatment Usage Patterns, (million), 2010-2017 57

Table 45: Pulmonary Arterial Hypertension Therapeutics Market, Global, Revenue, ($m), 2002-2010 62

Table 46: Pulmonary Arterial Hypertension Therapeutics Market, Global, Revenue Forecasts, ($m), 2010-2017 62

Table 47: Pulmonary Arterial Hypertension Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2010 63

Table 48: Pulmonary Arterial Hypertension Therapeutics Market, Global, Geographical Segmentation, ($m), 2010-2017 64

Table 49: Pulmonary Arterial Hypertension Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2010 66

Table 50: Pulmonary Arterial Hypertension Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010-2017 66

Table 51: Pulmonary Arterial Hypertension Therapeutics Market, Global, Treatment Usage Patterns, ('000), 2002-2010 67

Table 52: Pulmonary Arterial Hypertension Therapeutics Market, Global, Treatment Usage Patterns, ('000), 2010-2017 67

Table 53: Cystic Fibrosis Therapeutics Market, Global, Revenue, ($m), 2002-2010 71

Table 54: Cystic Fibrosis Therapeutics Market, Global, Revenue Forecasts, ($m), 2010-2017 72

Table 55: Cystic Fibrosis Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2010 73

Table 56: Cystic Fibrosis Therapeutics Market, Global, Geographical Segmentation, ($m), 2010-2017 74

Table 57: Cystic Fibrosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2010 76

Table 58: Cystic Fibrosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010-2017 76

Table 59: Cystic Fibrosis Therapeutics Market, Global, Treatment Usage Patterns, ('000), 2002-2010 77

Table 60: Cystic Fibrosis Therapeutics Market, Global, Treatment Usage Patterns, ('000), 2010-2017 77

Table 61: Allergic Rhinitis Therapeutics Market, Global, Revenue, ($m), 2002-2010 81

Table 62: Allergic Rhinitis Therapeutics Market, Global, Revenue Forecasts, ($m), 2010-2017 82

Table 63: Allergic Rhinitis Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2010 83

Table 64: Allergic Rhinitis Therapeutics Market, Global, Geographical Segmentation, ($m), 2010-2017 84

Table 65: Allergic Rhinitis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2010 86

Table 66: Allergic Rhinitis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010-2017 86

Table 67: Allergic Rhinitis Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2010 87

Table 68: Allergic Rhinitis Therapeutics Market, Global, Treatment Usage Patterns (million), 2010-2017 88

Table 69: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Revenue, ($m) 2002-2010 90

Table 70: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Revenue Forecasts, ($m) 2010-2017 90

Table 71: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Geographical Segmentation, ($m) 2002-2010 91

Table 72: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Geographical Segmentation, ($m) 2010-2017 92

Table 73: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2010 94

Table 74: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Annual Cost of Therapy, ($) 2010-2017 94

Table 75: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Treatment Usage Patterns, ('000), 2002-2010 95

Table 76: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Treatment Usage Patterns, ('000), 2010-2017 96

Table 77: Bronchitis Therapeutics Market, Global, Revenue ($m), 2002-2010 99

Table 78: Bronchitis Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017 100

Table 79: Bronchitis Therapeutics Market, Global, Geographical Segmentation ($m), 2002-2010 101

Table 80: Bronchitis Therapeutics Market, Global, Geographical Segmentation ($m), 2010-2017 102

Table 81: Bronchitis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2010 104

Table 82: Bronchitis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010-2017 104

Table 83: Bronchitis Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2010 105

Table 84: Bronchitis Therapeutics Market, Global, Treatment Usage Patterns (million), 2010-2017 105

Table 85: Respiratory Disorders Therapeutics Market, Global Product Pipeline by Phase, 2011 109

Table 86: Respiratory Disorders Therapeutics Market, Global Product Pipeline by Indication, 2011 110

Table 87: Asthma Therapeutics Market, Pipeline, Discovery Stage Molecules, 2011 111

Table 88: Asthma Therapeutics Market, Pipeline, Pre-Clinical Stage Molecules, 2011 111

Table 89: Asthma Therapeutics Market, Pipeline, Phase I Molecules, 2011 113

Table 90: Asthma Therapeutics Market, Pipeline, Phase II Molecules, 2011 114

Table 91: Asthma Therapeutics Market, Pipeline, Phase III Molecules, 2011 116

Table 92: Asthma Therapeutics Market, Pipeline, NDA Filed Molecules, 2011 116

Table 93: COPD Therapeutics Market, Pipeline, Discovery Stage Molecules, 2011 117

Table 94: COPD Therapeutics Market, Pipeline, Pre-Clinical Stage Molecules, 2011 117

Table 95: COPD Therapeutics Market, Pipeline, Phase I Molecules, 2011 118

Table 96: COPD Therapeutics Market, Pipeline, Phase II Molecules, 2011 119

Table 97: COPD Therapeutics Market, Pipeline, Phase III Molecules, 2011 120

Table 98: COPD Therapeutics Market, Pipeline, NDA Filed Molecules, 2011 120

Table 99: Pulmonary Arterial Hypertension Therapeutics Market, Pipeline, Pre-Clinical Stage Molecules, 2011 121

Table 100: Pulmonary Arterial Hypertension Therapeutics Market, Pipeline, Phase I Molecules, 2011 121

Table 101: Pulmonary Arterial Hypertension Therapeutics Market, Pipeline, Phase II Molecules, 2011 121

Table 102: Pulmonary Arterial Hypertension Therapeutics Market, Pipeline, Phase III Molecules, 2011 122

Table 103: Pulmonary Arterial Hypertension Therapeutics Market, Pipeline, NDA Molecules, 2011 122

Table 104: Cystic Fibrosis Therapeutics Market, Pipeline, Pre-Clinical Stage Molecules, 2011 123

Table 105: Cystic Fibrosis Therapeutics Market, Pipeline, Phase I Molecules, 2011 123

Table 106: Cystic Fibrosis Therapeutics Market, Pipeline, Phase II Molecules, 2011 123

Table 107: Cystic Fibrosis Therapeutics Market, Pipeline, Phase III Molecules, 2011 124

Table 108: Cystic Fibrosis Therapeutics Market, Pipeline, NDA Filed Molecules, 2011 124

Table 109: Allergic Rhinitis Therapeutics Market, Pipeline, Discovery Stage Molecules, 2011 125

Table 110: Allergic Rhinitis Therapeutics Market, Pipeline, Pre-Clinical Stage Molecules, 2011 125

Table 111: Allergic Rhinitis Therapeutics Market, Pipeline, Phase I Molecules, 2011 125

Table 112: Allergic Rhinitis Therapeutics Market, Pipeline, Phase II Molecules, 2011 126

Table 113: Allergic Rhinitis Therapeutics Market, Pipeline, Phase III Molecules, 2011 127

Table 114: Idiopathic Pulmonary Fibrosis Therapeutics Market, Pipeline, Pre-Clinical Stage Molecules, 2011 128

Table 115: Idiopathic Pulmonary Fibrosis Therapeutics Market, Pipeline, IND Filed Molecules, 2011 128

Table 116: Idiopathic Pulmonary Fibrosis Therapeutics Market, Pipeline, Phase I Molecules, 2011 128

Table 117: Idiopathic Pulmonary Fibrosis Therapeutics Market, Pipeline, Phase II Molecules, 2011 128

Table 118: Idiopathic Pulmonary Fibrosis Therapeutics Market, Pipeline, Phase III Molecules, 2011 129

Table 119: Idiopathic Pulmonary Fibrosis Therapeutics Market, Pipeline, NDA Filed Molecules, 2011 129

Table 120: Bronchitis Therapeutics Market, Pipeline, Discovery Stage Molecules, 2011 130

Table 121: Bronchitis Therapeutics Market, Pipeline, Pre-Clinical Stage Molecules, 2011 130

Table 122: Bronchitis Therapeutics Market, Pipeline, Phase I Molecules, 2011 130

Table 123: Bronchitis Therapeutics Market, Pipeline, Phase II Molecules, 2011 130

Table 124: Bronchitis Therapeutics Market, Pipeline, Phase III Molecules, 2011 130

Table 125: Bronchitis Therapeutics Market, Pipeline, NDA Filed Molecules, 2011 130

Table 126: Respiratory Disorders Therapeutics Market to 2017, Sales of Major Marketed Products, ($m), 2010 138

Table 127: Respiratory Disorders Therapeutics Market, Global, M&A Deals by Value ($m), 2004-2011 156

Table 128: Respiratory Disorders Therapeutics Market, Global, M&A Deals by Geography, 2004-2011 157

Table 129: Respiratory Disorders Therapeutics Market, Global, M&A Deals by Deal Type, 2004-2011 158

Table 130: Respiratory Disorders Therapeutics Market, Global, Deals by Deal Sub-Type, 2004-2011 159

Table 131: Respiratory Disorders Therapeutics Market, Global, Licensing Agreements by Geography (%), 2004-2011 161

Table 132: Respiratory Disorders Therapeutics Market, Global, Licensing Agreements by Value ($m), 2004-2011 162

Table 133: Respiratory Disorders Therapeutics Market, Global, Co-Development Agreements by Geography, 2004-2011 164

1.2 List of Figures

Figure 1: Respiratory Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 15

Figure 2: Respiratory Disorders Therapeutics Market, Global, Geographical Segmentation ($bn), 2002-2017 17

Figure 3: Respiratory Disorders Therapeutics Market, Global, Branded and Generic Share (%), 2010 19

Figure 4: Respiratory Disorders Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017 20

Figure 5: Respiratory Disorders Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2017 21

Figure 6: Respiratory Disorders Therapeutics Market, Global, Drivers and Barriers, 2010 23

Figure 7: Respiratory Disorders Therapeutics Market, The US, Revenue Forecasts, ($bn), 2002-2017 25

Figure 8: Respiratory Disorders Therapeutics Market, The US, Annual Cost of Therapy, ($), 2002-2017 26

Figure 9: Respiratory Disorders Therapeutics Market, The US, Treatment Usage Patterns, (million), 2002-2017 27

Figure 10: Respiratory Disorders Therapeutics Market, Top Five Countries, Revenue Forecasts, ($bn), 2002-2017 29

Figure 11: Respiratory Disorders Therapeutics Market, Top Five Countries, Revenue Share by Country Forecasts, ($bn), 2002-2017 30

Figure 12: Respiratory Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy, ($), 2002-2017 32

Figure 13: Respiratory Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns, (million), 2002-2017 33

Figure 14: Respiratory Disorders Therapeutics Market, Japan, Revenue Forecasts, ($bn), 2002-2017 35

Figure 15: Respiratory Disorders Therapeutics Market, Japan, Annual Cost of Therapy, ($), 2002-2017 36

Figure 16: Respiratory Disorders Therapeutics Market, Japan, Treatment Usage Patterns, (million), 2002-2017 37

Figure 17: Asthma Therapeutics Market, Global, Revenue Forecasts, ($bn), 2002-2017 39

Figure 18: Asthma Therapeutics Market, Global, Geographical Segmentation, ($bn), 2002-2017 41

Figure 19: Asthma Therapeutics Market, Global, Branded and Generic Share, (%), 2010 43

Figure 20: Asthma Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2017 44

Figure 21: Asthma Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002-2017 45

Figure 22: Asthma Therapeutics Market, Global, Treatment Flow Algorithm, 2010 47

Figure 23: Asthma Therapeutics Market, Global, Drivers and Barriers, 2010 48

Figure 24: COPD Therapeutics Market, Global, Revenue Forecasts, ($m), 2002-2017 50

Figure 25: COPD Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2017 52

Figure 26: COPD Therapeutics Market, Global, Branded and Generic Share, (%), 2010 54

Figure 27: COPD Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2017 55

Figure 28: COPD Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002-2017 56

Figure 29: COPD Therapeutics Market, Global, Treatment Flow Algorithm - 1, 2010 58

Figure 30: COPD Therapeutics Market, Global, Treatment Flow Algorithm - 2, 2010 58

Figure 31: COPD Therapeutics Market, Global, Drivers and Barriers, 2010 59

Figure 32: Pulmonary Arterial Hypertension Therapeutics Market, Global, Revenue Forecasts, ($m), 2002-2017 62

Figure 33: Pulmonary Arterial Hypertension Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2017 63

Figure 34: Pulmonary Arterial Hypertension Therapeutics Market, Global, Branded and Generic Share, (%), 2010 65

Figure 35: Pulmonary Arterial Hypertension Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2017 66

Figure 36: Pulmonary Arterial Hypertension Therapeutics Market, Global, Treatment Usage Patterns, ('000), 2002-2017 67

Figure 37: Pulmonary Arterial Hypertension Therapeutics Market, Global, Treatment Flow Algorithm, 2010 69

Figure 38: Pulmonary Arterial Hypertension Therapeutics Market, Global, Drivers and Barriers, 2010 70

Figure 39: Cystic Fibrosis Therapeutics Market, Global, Revenue Forecasts, ($m), 2002-2017 71

Figure 40: Cystic Fibrosis Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2017 73

Figure 41: Cystic Fibrosis Therapeutics Market, Global, Branded and Generic Share, (%), 2010 75

Figure 42: Cystic Fibrosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2017 76

Figure 43: Cystic Fibrosis Therapeutics Market, Global, Treatment Usage Patterns, ('000), 2002-2017 77

Figure 44: Cystic Fibrosis Therapeutics Market, Global, Treatment Flow Algorithm, 2010 79

Figure 45: Cystic Fibrosis Therapeutics Market, Global, Drivers and Barriers, 2010 80

Figure 46: Allergic Rhinitis Therapeutics Market, Global, Revenue Forecasts, ($m), 2002-2017 81

Figure 47: Allergic Rhinitis Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2017 83

Figure 48: Allergic Rhinitis Therapeutics Market, Global, Branded and Generic Share, (%), 2010 85

Figure 49: Allergic Rhinitis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2017 86

Figure 50: Allergic Rhinitis Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2017 87

Figure 51: Allergic Rhinitis Therapeutics Market, Global, Treatment Flow Algorithm, 2010 88

Figure 52: Allergic Rhinitis Therapeutics Market, Global, Drivers and Barriers, 2010 89

Figure 53: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Revenue Forecasts, ($m) 2002-2017 90

Figure 54: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Geographical Segmentation, ($m) 2002-2017 91

Figure 55: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Branded and Generic Share, (%), 2010 93

Figure 56: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2017 94

Figure 57: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Treatment Usage Patterns, ('000), 2002-2017 95

Figure 58: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Treatment Flow Algorithm, 2010 97

Figure 59: Allergic Rhinitis Therapeutics Market, Global, Drivers and Barriers, 2010 98

Figure 60: Bronchitis Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017 99

Figure 61: Bronchitis Therapeutics Market, Global, Geographical Segmentation ($m), 2002-2017 101

Figure 62: Bronchitis Therapeutics Market, Global, Branded and Generic Share (%), 2010 103

Figure 63: Bronchitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017 104

Figure 64: Bronchitis Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2017 105

Figure 65: Bronchitis Therapeutics Market, Global, Treatment Flow Algorithm, 2010 107

Figure 66: Bronchitis Therapeutics Market, Global, Drivers and Barriers, 2010 108

Figure 67: Respiratory Disorders Therapeutics Market, Global Product Pipeline by Phase (%), 2011 109

Figure 68: Respiratory Disorders Therapeutics Market, Global Product Pipeline by Indication (%), 2011 110

Figure 69: Respiratory Disorders Therapeutics Market, Global, Market Share Analysis by Company (%), 2010 137

Figure 70: Respiratory Disorders Therapeutics Market, AstraZeneca, Company Overview, 2011 145

Figure 71: Respiratory Disorders Therapeutics Market, AstraZeneca, SWOT Analysis, 2011 146

Figure 72: Respiratory Disorders Therapeutics Market, GSK, Company Overview, 2011 147

Figure 73: Respiratory Disorders Therapeutics Market, GSK, SWOT Analysis, 2011 148

Figure 74: Respiratory Disorders Therapeutics Market, Merck, Company Overview, 2011 149

Figure 75: Respiratory Disorders Therapeutics Market, Merck, SWOT Analysis, 2011 150

Figure 76: Respiratory Disorders Therapeutics Market, Actelion, Company Overview, 2011 151

Figure 77: Respiratory Disorders Therapeutics Market, Actelion, SWOT Analysis, 2011 152

Figure 78: Respiratory Disorders Therapeutics Market, Novartis, Company Overview, 2011 153

Figure 79: Respiratory Disorders Therapeutics Market, Novartis, SWOT Analysis, 2011 154

Figure 80: Respiratory Disorders Therapeutics Market, Global, M&A Deals by Year, 2004-2011 155

Figure 81: Respiratory Disorders Therapeutics Market, Global, M&A Deals by Value (%), 2004-2011 156

Figure 82: Respiratory Disorders Therapeutics Market, Global, M&A Deals by Geography (%), 2004-2011 157

Figure 83: Respiratory Disorders Therapeutics Market, Global, M&A Deals by Deal Type (%), 2004-2011 158

Figure 84: Respiratory Disorders Therapeutics Market, Global, Deals by Deal Sub-Type (%), 2004-2011 159

Figure 85: Respiratory Disorders Therapeutics Market, Global, Licensing Agreements by Year, 2004-2011 160

Figure 86: Respiratory Disorders Therapeutics Market, Global, Licensing Agreements by Geography (%), 2004-2011 161

Figure 87: Respiratory Disorders Therapeutics Market, Global, Licensing Agreements by Value (%), 2004-2011 162

Figure 88: Respiratory Disorders Therapeutics Market, Global, Co-Development Agreements by Year, 2004-2011 163

Figure 89: Respiratory Disorders Therapeutics Market, Global, Co-Development Agreements by Geography (%), 2004-2011 164

Figure 90: GBI Research Market Forecasting Model 169

Companies Mentioned

AstraZeneca

GlaxoSmithKline

Merck & Co., Inc.

Actelion

Novartis

To order this report:

Pathology Industry: Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and pirfenidone May Offset Negative Effect of Patent Expiries

Pathology Business News

More  Market Research Report

Check our  Industry Analysis and Insights

__________________________

Contact Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker